Evidence map›Paper›PMID 39345541›Full record

ArticlebioRxiv : the preprint server for biology2024

Tenascin-C in the early lung cancer tumor microenvironment promotes progression through integrin αvβ1 and FAK.

Shiela C Samson, Anthony Rojas, Rebecca G Zitnay, Keith R Carney, Wakeiyo Hettinga, Mary C Schaelling, Delphine Sicard, Wei Zhang, Melissa Gilbert-Ross, Grace K Dy and 13 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Shiela C SamsonDepartment of Oncological Sciences, University of Utah, Salt Lake City, UT 84112.
Anthony RojasDepartment of Oncological Sciences, University of Utah, Salt Lake City, UT 84112.
Rebecca G ZitnayHuntsman Cancer Institute, Salt Lake City, UT 84112.
Keith R CarneyDepartment of Oncological Sciences, University of Utah, Salt Lake City, UT 84112.
Wakeiyo HettingaHuntsman Cancer Institute, Salt Lake City, UT 84112.
Mary C SchaellingDepartment of Oncological Sciences, University of Utah, Salt Lake City, UT 84112.
Delphine SicardDepartment of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN 55905.
Wei ZhangHuntsman Cancer Institute, Salt Lake City, UT 84112.
Melissa Gilbert-RossDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322.
Grace K DyDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203.
Michael J CavnarDepartment of Surgery, University of Kentucky, Lexington, KY 40508.
Muhammad FurqanDepartment of Internal Medicine, University of Iowa Health Care, Iowa City, IA 52246.
Robert F BrowningDepartment of Medicine, Walter Reed National Military Medical Center, Bethesda, MD 20889.
Abdul R NaqashDivision of Medical Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104.
Bryan P SchneiderDepartment of Hematology and Oncology, Indiana University School of Medicine, Indianapolis, IN 46202.
Ahmad TarhiniDepartments of Cutaneous Oncology and Immunology, H. Lee Moffit Cancer Center & Research Institute, Tampa, FL 33612.
Daniel J TschumperlinDepartment of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN 55905.
Alessandro VenosaDepartment of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112.
Adam I MarcusDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322.
Lyska L EmersonHuntsman Cancer Institute, Salt Lake City, UT 84112.
Benjamin T SpikeDepartment of Oncological Sciences, University of Utah, Salt Lake City, UT 84112.
Beatrice S KnudsenHuntsman Cancer Institute, Salt Lake City, UT 84112.
Michelle C MendozaDepartment of Oncological Sciences, University of Utah, Salt Lake City, UT 84112.ORCID 0000-0002-6490-1794

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6M
Cancer invasion: reciprocity between the extracellular matrix and intrinsic ERK signalingR01CA255790 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Michelle Christine Mendoza · 2022 to 2026
$2.3M
NCI NIH HHS P30 CA042014NCI NIH HHS R01 CA255790
6 · The paper itself

Abstract

Pre-cancerous lung lesions are commonly initiated by activating mutations in the RAS pathway, but do not transition to lung adenocarcinomas (LUAD) without additional oncogenic signals. Here, we show that expression of the extracellular matrix protein Tenascin-C (TNC) is increased in and promotes the earliest stages of LUAD development in oncogenic KRAS-driven lung cancer mouse models and in human LUAD. TNC is initially expressed by fibroblasts and its expression extends to tumor cells as the tumor becomes invasive. Genetic deletion of TNC in the mouse models reduces early tumor burden and high-grade pathology and diminishes tumor cell proliferation, invasion, and focal adhesion kinase (FAK) activity. TNC stimulates cultured LUAD tumor cell proliferation and migration through engagement of αv-containing integrins and subsequent FAK activation. Intringuingly, lung injury causes sustained TNC accumulation in mouse lungs, suggesting injury can induce additional TNC signaling for early tumor cell transition to invasive LUAD. Biospecimens from patients with stage I/II LUAD show TNC in regions of FAK activation and an association of TNC with tumor recurrence after primary tumor resection. These results suggest that exogenous insults that elevate TNC in the lung parenchyma interact with tumor-initiating mutations to drive early LUAD progression and local recurrence.

Identifiers

PMID39345541
PMCPMC11429853

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.